Meeting abstracts from the Annual Conference on Hereditary Cancers 2015
Ella R. Thompson(Peter MacCallum Cancer Centre), Andrzej Pławski(Poznan University of Medical Sciences), Barbara Jarząb(The Maria Sklodowska-Curie National Research Institute of Oncology), Na Lil(The University of Melbourne), Cliff Meldrum(New South Wales Department of Health), Edvīns Miklaševičs(Riga Stradiņš University), Paul A. James(The Royal Melbourne Hospital), Rodney J. Scott(New South Wales Department of Health), Małgorzata Kowalska(Medical University of Silesia), Michał Jarząb(The Maria Sklodowska-Curie National Research Institute of Oncology), Agnieszka Czarniecka(The Maria Sklodowska-Curie National Research Institute of Oncology), Tomasz Tyszkiewicz(The Maria Sklodowska-Curie National Research Institute of Oncology), Dagmara Rusinek(The Maria Sklodowska-Curie National Research Institute of Oncology), Alison H. Trainer(The Royal Melbourne Hospital), Arvīds Irmejs(University of Parma), Ian Campbell(The University of Sydney), Katarzyna Klonowska(Institute of Bioorganic Chemistry, Polish Academy of Sciences), Monika Kowal(The Maria Sklodowska-Curie National Research Institute of Oncology), Miki Nakazawa(Riga Stradiņš University), Genādijs Trofimovičs(Riga Stradiņš University), Anna Jakubowska(Pomeranian Medical University), Simone McInerny(Peter MacCallum Cancer Centre), Cate Smith(The University of Melbourne), Simone M. Rowley(Victorian Clinical Genetics Services), Michelle W. Wong‐Brown(Peter MacCallum Cancer Centre), Jeļena Maksimenko(Riga Stradiņš University), Jolanta Krajewska(The Maria Sklodowska-Curie National Research Institute of Oncology), Ewa Grzybowska(The Maria Sklodowska-Curie National Research Institute of Oncology), Michael Hipwell(New South Wales Department of Health), Jānis Gardovskis(Riga Stradiņš University), David Mossman(University of Newcastle Australia), S Dooley(John Hunter Hospital), Inga Melbārde-Gorkuša(Riga Stradiņš University), Jolanta Pamuła‐Piłat(The Maria Sklodowska-Curie National Research Institute of Oncology), Joanna Łanuszewska(The Maria Sklodowska-Curie National Research Institute of Oncology), Karolina Tęcza(The Maria Sklodowska-Curie National Research Institute of Oncology), Agnieszka Pawlaczek(The Maria Sklodowska-Curie National Research Institute of Oncology), M. Gełej(Lublin Oncology Center), J. Tomiczek-Szwiec(Lublin Oncology Center), Gillian Mitchell(Peter MacCallum Cancer Centre), Jadwiga Żebracka‐Gala(The Maria Sklodowska-Curie National Research Institute of Oncology), Briar-Rose Millar(Hunter Genetics), Michał Świerniak(Medical University of Warsaw), T. Huzarski(International Hereditary Cancer Center), E. Kilar, M. Szwiec(Lublin Oncology Center), Lisa Devereux(Peter MacCallum Cancer Centre), C. Cybulski(International Hereditary Cancer Center), Małgorzata Oczko‐Wojciechowska(The Maria Sklodowska-Curie National Research Institute of Oncology)
Cited by 0
Related Papers
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
|The Lancet|2010|1.6k
<i>BRCA</i> Mutation Frequency and Patterns of Treatment Response in <i>BRCA</i> Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group
|Journal of Clinical Oncology|2012|1.2k
Inflammatory subtypes in asthma: Assessment and identification using induced sputum
|Respirology|2006|939